STERIS plc Reports 8.7% Revenue Growth to $1.39 Billion in Q1 Fiscal 2026

STERIS plc reported a significant increase in financial performance for the first quarter of fiscal 2026, with total revenues reaching $1.39 billion, an 8.7% increase from $1.28 billion in the same period last year. The growth was driven by higher volumes and pricing across all three business segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. The company’s gross profit margin improved to 45.1%, up from 44.7% in the prior year, reflecting favorable pricing and productivity impacts, although partially offset by inflation and material costs.

Operating income for the quarter was $246 million, compared to $185.5 million in the previous year, marking a 32.5% increase. This rise in income was attributed to increased sales volume and pricing, alongside reduced restructuring expenses. Notably, restructuring costs fell to $1.8 million from $28.1 million a year earlier, as the company continues to implement its strategic restructuring plan initiated in May 2024, which included workforce reductions and facility consolidations.

In terms of operational metrics, STERIS reported cash flows from operations of $420 million, up from $303.7 million in the same quarter last year, contributing to a free cash flow of $326.5 million, compared to $195.7 million previously. The company’s debt-to-total capital ratio improved to 21.5% from 23.6% at the end of the previous fiscal year, indicating a stronger balance sheet. As of June 30, 2025, STERIS had 98.5 million ordinary shares outstanding.

Strategically, STERIS completed a tuck-in acquisition for approximately $15 million during the quarter, further expanding its product and service offerings in the Healthcare segment. The company also continues to benefit from the divestiture of its Dental segment, which was sold for $787.5 million in May 2024, allowing for a focus on core operations. Looking ahead, STERIS anticipates continued growth driven by increased demand for healthcare services and ongoing investments in product innovation and efficiency improvements.

Overall, STERIS plc's financial results reflect a positive trajectory, supported by strategic initiatives and a favorable market environment, positioning the company for sustained growth in the healthcare and life sciences sectors.